GN to Relocate North American Hearing Headquarters in 2025
The new 218,437 square-foot facility will support manufacturing, sales, and services for GN’s hearing aid brands.
Read MoreThe new 218,437 square-foot facility will support manufacturing, sales, and services for GN’s hearing aid brands.
Read MoreMed-El USA was honored with a Hearing Technology Innovator Award for OtoPlan in the cochlear implant category.
Read MoreContext and complexity can go a long way toward making what one person may consider dissonant sound quite pleasant to others.
Read MoreThe family film Rally Caps highlights the power of team building, friendship, and breaking down stigmas associated with hearing loss.
Read MoreThe Hearing Technology Innovator Awards 2024 competition attracted submissions from a diverse range of pioneering companies worldwide.
Read MoreThe 2024 Oticon Audiology Summer Camp brought together 50 graduate students in audiology for a week-long educational event.
Read MoreThe study found Lenire’s real-world effectiveness in treating tinnitus to be consistent with clinical trial results.
Read MoreSignia has announced Signia Active Pro IX, consumer earbuds that double as prescription-grade hearing aids.
Read MoreSensorion will lead a symposium at the 36th World Congress of Audiology in Paris called “Are we at the Dawn of a Hearing Loss Revolution?”
Read MoreChildren with developmental disabilities—1 in 6 children in the United States—are less likely to access a gold-standard hearing assessment in the first three months of hearing care, a recent paper reported.
Read MoreWhile frequency lowering to accommodate cochlear dead zones is relatively common, frequency raising is not—so far.
Read MoreCAA Conference 2024 will offer two pre-conference workshops and a program full of varied and relevant talks by leaders in the field.
Read MoreThe clinical innovation lab is improving the use of 3D printing for custom pediatric hearing aid earmolds to significantly improve efficiency in patient care.
Read MoreMany organizations find themselves violating HIPAA, not due to inadequate cybersecurity measures, but because of the human factor.
Read MoreThe PROHEAR study is a placebo-controlled Phase 2a study investigating the otoprotective efficacy of ACOU085 in patients with testicular cancer undergoing cisplatin-based chemotherapy.
Read More